drugset / Trial / NCT06461988
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
Multiple myeloma (MM) is a heterogenous plasma cell malignancy characterized by clonal proliferation of plasma cells and organ damage. Autologous transplantation with high dose chemotherapy is the standard of care in frontline treatment of eligible patients with MM.
Timeline
- Start
- 2025-06-05
- Primary completion
- 2027-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 5 mg | — |
| Subject | Lenalidomide | Other / unclassified | 10 mg | — |
| Subject | Talquetamab | Monoclonal antibody | 800 mg/kg | Subcutaneous |